LXRX vs TER · rev $21.8M vs P/E 76, rev $2.61B
Lexicon Pharmaceuticals Inc (LXRX) versus Teradyne Inc (TER) — a side-by-side from cached financials, not a winner call.
Lexicon Pharmaceuticals Inc (LXRX) is a biotechnology company listed on US.
Teradyne Inc (TER) is a semiconductor equipment & materials company listed on NASDAQ.
Latest reported LXRX revenue for 2026-06-30 was $21.8M. Net income was -$32.8M. Revenue was up 3.3% from 2026-03-31 to 2026-06-30. LXRX currently screens at market cap $327.2M.
Latest reported TER revenue for 2026-06-28 was $2.61B. Net income was $773.4M. TER currently screens at market cap $63.96B and trailing P/E 75.7.
LXRX currently screens at market cap $327.2M. TER currently screens at market cap $63.96B and trailing P/E 75.7.
Not investment advice. Open the LXRX and TER stock pages for the full models.
Not investment advice.